Please login to the form below
anti-NGF
This page shows the latest anti-NGF news and features for those working in and with pharma, biotech and healthcare.
FDA halts study of Teva and Regeneron's pain drug fasinumab
Arthropathy has been seen before with NGF inhibitors - and caused the agency to put the entire class under a clinical hold in 2011. ... Eli Lilly and partner Pfizer also remain in the race with their tanezumab anti-NGF candidate, which restarted testing
Latest news
-
Regeneron says anti-NGF fasinumab works in pain
That hold was subsequently relaxed to a partial hold, allowing some drugmakers to resume testing and leading to optimism that anti-NGF programmes may get back on track. ... The decision was attributed to shifting commercial priorities rather than a
-
Lilly eyes pivotal trials for pain drug tanezumab in 2015
The antibody drug targets nerve growth factor (NGF) and - if approved - would represent a completely new drug class for chronic pain conditions, including osteoarthritis and cancer-related pain. ... In 2012 however a new partial clinical hold on the
-
J&J chief predicts 10 new pharma filings by 2017
Among the pipeline projects highlighted by Gorsky are esketamine, a glutamate NMDA antagonist that he described as a "potential breakthrough medication" for treatment-resistant depression, as well as anti-CD38 antibody ... Fulranumab, an anti-nerve
-
Pfizer sales down but oncology shows promise
There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a ... The company has also joined forces with Lilly to
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
